Brokerages Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Target Price at $6.25

by · The Cerbat Gem

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $6.25.

Several research firms have issued reports on ONCY. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Zacks Research raised shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. HC Wainwright raised their target price on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 1st. Finally, Lake Street Capital initiated coverage on Oncolytics Biotech in a research note on Wednesday, August 13th. They issued a “buy” rating and a $7.00 price objective on the stock.

Get Our Latest Research Report on ONCY

Institutional Investors Weigh In On Oncolytics Biotech

Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech in the third quarter valued at $535,000. Scientech Research LLC bought a new stake in shares of Oncolytics Biotech during the 3rd quarter worth about $25,000. Finally, Seeds Investor LLC grew its stake in Oncolytics Biotech by 17.8% in the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after buying an additional 33,826 shares during the last quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY opened at $0.99 on Tuesday. The stock has a 50 day moving average price of $1.13 and a 200 day moving average price of $1.00. The stock has a market capitalization of $99.57 million, a PE ratio of -3.54 and a beta of 0.88. Oncolytics Biotech has a 52 week low of $0.33 and a 52 week high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. As a group, research analysts forecast that Oncolytics Biotech will post -0.28 EPS for the current year.

About Oncolytics Biotech

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Further Reading